NEWS
OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key U.S. Patent No. 12,053,501 which issued on August 6thentitled: "Methods for Treating Symptoms of Dry Eye Disease". The present disclosure covers issued claims on OK-101's use to treat irritated, burning eyes and blurred vision in patients suffering from DED, strengthening the Company's intellectual property position in this field.
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today the grant of a key U.S. Patent No. 12,053,501 which issued on August 6thentitled: "Methods for Treating Symptoms of Dry Eye Disease". The present disclosure covers issued claims on OK-101's use to treat irritated, burning eyes and blurred vision in patients suffering from DED, strengthening the Company's intellectual property position in this field.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1825Followers
98Following
15KVisitors
Follow